Evidence map›Paper›PMID 40372913›Full record

ArticleCell reports2025

Acute infectious mononucleosis generates persistent, functional EBNA-1 antibodies with high cross-reactivity to alpha-crystalline beta.

Krishna Kumar Ganta, Margaret McManus, Ross Blanc, Qixin Wang, Wonyeong Jung, Robin Brody, Mary Carrington, Robert Paris, Sumana Chandramouli, Ryan P McNamara and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Krishna Kumar GantaMolecular Medicine, UMass Chan Medical School, Worcester, MA 01605, USA.
Margaret McManusMolecular Medicine, UMass Chan Medical School, Worcester, MA 01605, USA.
Ross BlancRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Qixin WangRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Wonyeong JungRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.
Robin BrodyMolecular Medicine, UMass Chan Medical School, Worcester, MA 01605, USA.
Mary CarringtonRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20814, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21701, USA.
Robert ParisModerna Therapeutics, Cambridge, MA 02142, USA.
Sumana ChandramouliModerna Therapeutics, Cambridge, MA 02142, USA.
Ryan P McNamaraRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Electronic address: rmcnamara@hsph.harvard.edu.
Katherine LuzuriagaMolecular Medicine, UMass Chan Medical School, Worcester, MA 01605, USA. Electronic address: katherine.luzuriaga@umassmed.edu.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
University of Massachusetts Center for Clinical Science and Translational SupplementUL1TR001453 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2015 to 2024
$39.0M
NCATS NIH HHS UL1 TR001453NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

We investigate the magnitude, specificity, and functional properties of Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1)-specific antibodies in young adults over the course of primary infection. EBNA-1-specific binding antibodies, as well as antibodies capable of antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent complement deposition (ADCD), are detected. These antibodies primarily target a region of EBNA-1 known to elicit cross-reactive antibodies to several self-peptides. Higher EBNA-1 binding and ADCD antibodies are observed in individuals with at least one HLA-DRB1

Indexed as

Antibodies, ViralEpstein-Barr Virus Nuclear AntigensInfectious MononucleosisAdultCross ReactionsFemaleHerpesvirus 4, HumanHLA-DRB1 ChainsHumansMaleYoung AdultAntibodies, ViralEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensHLA-DRB1 Chainsalpha-crystalline betacomplement depositionCP: ImmunologyCP: MicrobiologyEBNA-1EBVHLA-DRB1(∗)15:01infectious mononucleosismolecular mimicrymultiple sclerosis

Identifiers

PMID40372913
PMCPMC12235536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.